Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4797405
Max Phase: Preclinical
Molecular Formula: C38H41N9O11S
Molecular Weight: 831.87
Molecule Type: Unknown
Associated Items:
ID: ALA4797405
Max Phase: Preclinical
Molecular Formula: C38H41N9O11S
Molecular Weight: 831.87
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCOCCn1cc(COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nn1
Standard InChI: InChI=1S/C38H41N9O11S/c1-39-34(51)31-35(43-36(59-31)23-9-10-40-28(19-23)41-32(49)22-5-6-22)57-18-17-56-16-15-55-14-13-54-12-11-46-20-24(44-45-46)21-58-27-4-2-3-25-30(27)38(53)47(37(25)52)26-7-8-29(48)42-33(26)50/h2-4,9-10,19-20,22,26H,5-8,11-18,21H2,1H3,(H,39,51)(H,40,41,49)(H,42,48,50)
Standard InChI Key: FEICDSOLEYDNQO-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 831.87 | Molecular Weight (Monoisotopic): 831.2646 | AlogP: 1.61 | #Rotatable Bonds: 21 |
Polar Surface Area: 244.39 | Molecular Species: NEUTRAL | HBA: 17 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 20 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.43 | CX Basic pKa: 2.20 | CX LogP: 1.09 | CX LogD: 1.09 |
Aromatic Rings: 4 | Heavy Atoms: 59 | QED Weighted: 0.08 | Np Likeness Score: -1.33 |
1. Jiang X,Zhou J,Wang Y,Liu X,Xu K,Xu J,Feng F,Sun H. (2021) PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases., 210 [PMID:33097303] [10.1016/j.ejmech.2020.112949] |
Source(1):